Chief Executive Officer, Tolero Pharmaceuticals
Proventa International will be gathering over 100 C-Level Directors from a mix of emerging to large Pharmaceutical, Biotechnology & Academic/Research Institutions to help solve their key strategic challenges in the area of Oncology.Register Now
The Oncology Roundtable Discussions Strategy Meeting is free to attend for qualified end-users. These include Senior Executives of Oncology/Immuno-Oncology (from medium to large Pharma, Biopharma and Biotech players) in global development positions spanning early development to phase IV, as well as thought leaders from Academia and regulatory authorities.
Thought leaders who will benefit from attending include CXOs, EVPs, SVPs, VPs, Executive Directors, Directors and Global Heads responsible for:
– Oncology R&D,Translational Research/Development/Medicine, Clinical Research/Development, Immuno-Oncology, Medical Affairs Oncology,Clinical Pharmacology,Oncology Clinical Biostatistics and Programming, Oncology Clinical Genomics and Computational Biology, Oncology R&D Innovation, Oncology R&D Strategy, Oncology Portfolio/Project Management.
Those who do not qualify for complimentary passes, including vendors, exchanges, consultancies and other service providers, can apply here.
Senior Vice President, Global Head of Research & Early Development, Immunology & Neurology
President and Chief Medical Officer, Kyowa Kirin Pharmaceutical Development, Inc.
Dr. Humphrey previously served as VP of Oncology at both Bristol-Myers Squibb and Bayer Pharmaceuticals, and Clinical Exploratory Head of Oncology at Pfizer. Dr. Humphrey’s work over the past 20 years has included oversight or direct involvement in development of experimental and marketed oncology medicines, including submissions and/or launches of Sprycel, Ixempra, Yervoy, Erbitux, Nexavar, Ftorafur, and Taxol. He has developed specialized knowledge in anti-angiogenesis, companion diagnostics, and immuno-oncology during his career.
Dr. Humphrey holds an A.B., cum laude, from Harvard University in applied mathematics, anMD, Alpha Omega Alpha, from Case Western University School of Medicine, and completed his internal medicine internship and residency at the Johns Hopkins Hospital. Dr. Humphrey served as chief oncology fellow at the US NIH National Cancer Institute where he published original research in cell biology, biochemistry and molecular biology while completing fellowships in human medical genetics and medical oncology. Dr. Humphrey has co-authored multiple peer-reviewed publications, book chapters, and a patent, and has served as invited chairman and presenter at numerous academic and industry conferences.
Translational Sciences in Oncology: From the bench to the clinic and back againHarsukh Parmar
Senior Vice President, Global Head of Research & Early Development, Immunology & Neurology, EMD Serono
Associate Vice President, Global Head of Biostatistics, Oncology, Sanofi
Zhenming has been involved in multiple PhRMA working groups, including PFS and Clinical Trial Advocacy groups. Zhenming is the author of many publications, and presentations, on influential statistical and medical journals and professional conferences / workshops. His statistical research interests include adaptive designs in clinical trials, longitudinal data and categorical data, random effect models.
Zhenming received his Ph.D. in statistics from the University of Chicago.
Vice President, Head Academic Medical Innovation, Novartis
Dr Scherer began his career in the pharmaceutical industry at Grunenthal USA Inc, a partner of Johnson & Johnson, in 2005. He also spent 6 years at Roche/Genentech where he progressed to Vice President, Biomarker Head. Prior to joining Novartis, Dr Scherer was the Chief Medical Officer of Biocartis.
Dr Scherer obtained his MD from the University of Freiburg, Germany and University of Saarbrücken Medical School, Germany and his PhD from the University of Würzburg, Germany. He also has a postgraduate degree in bioinformatics from the Universities of Heidelberg and Mannheim, Germany and was a postdoctoral research associate at the Albert Einstein College of Medicine, New York City, NY, USA. Dr Scherer has over 16 years of combined medical, scientific research and business experience, and is a co-inventor on over 15 patent applications (mainly diagnostic tools and predictive biomarkers). He is also a core member of senior management and a presenter at regulatory agency interactions, including European (EMEA) and American (FDA) regulatory agencies for critical meetings (e.g. ODAC, CHMP, pre-IDE, NOOH, SAG-O, Type II & Type-C meetings) and CFDA interactions.
Vice President, Early Oncology Development, AbbVie
Vice President, Research and Development, MedImmune
In December 1992, Rakesh joined the Department of Safety Assessment, Merck and Co., Inc, West Point, PA where he served in various management positions. During his about 14 years with Merck, Rakesh contributed to the successful filings of many blockbuster drugs. For about a year, Rakesh was associated with Johnson and Johnson PRD, La Jolla/Alza as Senior Director of Toxicology.
In Aug 2006, Rakesh joined MedImmune, Inc. (an AstraZeneca Biologics company) as Senior Director (R &D) & Global Head of Biologics Safety Assessment, Experimental Pathology, and Laboratory Animal Medicine. In his current position as a Vice President of R &D since 2010, Rakesh is responsible for providing guidance on research and development of biological products; including nonclinical toxicology/safety support for all AstraZeneca-MedImmune biologics products, including monoclonal antibodies and vaccines. Rakesh has published more than 60 papers in renowned international journals and has given over 100 invited lectures/presentations/workshops in national and international meetings. Rakesh is one of the most invited speakers in the biotechnology industry.
Rakesh’s areas of expertise are mainly in the area of pharmaceuticals and biologics drug development, safety assessment of small molecule drugs, biologics, vaccines and in exploring mechanisms of toxicity and biologics pharmacological activity. Rakesh has helped to bring several blockbuster pharmaceuticals to the market while working at Merck. Rakesh a recognized expert in safety and pharmacology biomarkers and their applications.. Rakesh is the Editor-in- chief of Toxicology Mechanisms and Methods and Associate Editor for Toxicology Applied Pharmacology, and Journal of Toxicology and Environmental Health. Rakesh was selected by his pharmaceutical peers as the 100 Most Inspiring People in Pharmaceutical Industry by PharmaVOICE in 2015. Rakesh also serves as an expert reviewer and in appointed committee for many programs managed by the prestigious U.S. National Academy of Sciences and US National Institutes of Health, including National Cancer Institute.
SponsorsSEE OUR SPONSORS
Oncology Strategy Meeting USA East Coast 2016,
The Westin Boston Waterfront
425 Summer St, Boston, MA 02210